Clinical Applications Laboratories, Inc.

San Diego, California 92103-5639

1 studies enrolling now · 31 studies all time

What they study most

Celiac Disease, Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Diabetes Mellitus, Gastroesophageal Reflux, Gastroesophageal Reflux Disease (GERD), Gastroparesis, Heartburn, Irritable Bowel Syndrome, Moderately to Severely Active Crohns Disease, Non-Erosive Gastro-Esophageal Reflux Disease

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories — Completed
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Stopped early
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) — Completed
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission — Stopped early
• Diabetic Gastroparesis Study 05 — Stopped early
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis — Completed
• A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 — Stopped early
• Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) — Completed
• Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC — Stopped early
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis — Completed
• LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) — Completed
• Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms — Completed
• Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal — Completed
• Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH — Completed
• A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease — Completed